A dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with capecitabine (Xeloda) in patients with refractory solid tumors
- Author
- MALTEZOS, E1 ; AMARANTIDIS, K2 ; TRICHAS, M2 ; VASILIADIS, M1 ; TOROMANIDOU, M1 ; CHATZAKI, E3 ; KARAYIANNAKIS, A4 ; TSAROUCHA, A4 ; ROMANIDIS, K4 ; KAKOLYRIS, S2
[1] Department of Internal Medicine, School of Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece
[2] Department of Medical Oncology, School of Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece
[3] Department of Pharmacology, School of Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece
[4] Department of Surgery, School of Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece - Source
Oncology. 2005, Vol 69, Num 6, pp 463-469, 7 p ; ref : 27 ref
- ISSN
- 0030-2414
- Scientific domain
- Medical oncology
- Publisher
- Karger, Basel
- Publication country
- Switzerland
- Document type
- Article
- Language
- English
- Author keyword
- Capecitabine Pegylated liposomal doxorubicin Solid tumors
- Keyword (fr)
- Anticancéreux Cancérologie Capécitabine Dose croissante Doxorubicine Homme Liposome Résistance traitement Tumeur solide Inhibiteur topoisomerase II Anthracyclines DNA topoisomerase (ATP-hydrolysing) Enzyme Fluoropyrimidine dérivé Inhibiteur enzyme Isomerases Pyrimidine nucléoside Tumeur maligne
- Keyword (en)
- Antineoplastic agent Cancerology Capecitabine Increasing dose Doxorubicin Human Liposome Treatment resistance Solid tumor Anthracyclins DNA topoisomerase (ATP-hydrolysing) Enzyme Fluoropyrimidine derivatives Enzyme inhibitor Isomerases Pyrimidine nucleoside Malignant tumor
- Keyword (es)
- Anticanceroso Cancerología Capecitabina Dosis creciente Doxorubicina Hombre Liposoma Resistencia tratamiento Tumor sólido Antraciclinas DNA topoisomerase (ATP-hydrolysing) Enzima Fluoropirimidina derivado Inhibidor enzima Isomerases Pirimidina nucleósido Tumor maligno
- Classification
- Discipline
- Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17477285
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1159/000090494 
https://dx.doi.org/10.1159/000090494
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000090494\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:150:\"A dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with capecitabine (Xeloda) in patients with refractory solid tumors\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"69\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"463\";s:8:\"\u0000*\u0000epage\";s:3:\"469\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MALTEZOS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:14:\"AMARANTIDIS, K\";i:1;s:10:\"TRICHAS, M\";i:2;s:13:\"VASILIADIS, M\";i:3;s:14:\"TOROMANIDOU, M\";i:4;s:11:\"CHATZAKI, E\";i:5;s:16:\"KARAYIANNAKIS, A\";i:6;s:12:\"TSAROUCHA, A\";i:7;s:12:\"ROMANIDIS, K\";i:8;s:12:\"KAKOLYRIS, S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:150:\"A dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with capecitabine (Xeloda) in patients with refractory solid tumors\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000090494\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:150:\"A dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with capecitabine (Xeloda) in patients with refractory solid tumors\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"69\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"463\";s:8:\"\u0000*\u0000epage\";s:3:\"469\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MALTEZOS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:14:\"AMARANTIDIS, K\";i:1;s:10:\"TRICHAS, M\";i:2;s:13:\"VASILIADIS, M\";i:3;s:14:\"TOROMANIDOU, M\";i:4;s:11:\"CHATZAKI, E\";i:5;s:16:\"KARAYIANNAKIS, A\";i:6;s:12:\"TSAROUCHA, A\";i:7;s:12:\"ROMANIDIS, K\";i:8;s:12:\"KAKOLYRIS, S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:150:\"A dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with capecitabine (Xeloda) in patients with refractory solid tumors\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000090494\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000090494\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:150:\"A dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with capecitabine (Xeloda) in patients with refractory solid tumors\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"69\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"463\";s:8:\"\u0000*\u0000epage\";s:3:\"469\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MALTEZOS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:14:\"AMARANTIDIS, K\";i:1;s:10:\"TRICHAS, M\";i:2;s:13:\"VASILIADIS, M\";i:3;s:14:\"TOROMANIDOU, M\";i:4;s:11:\"CHATZAKI, E\";i:5;s:16:\"KARAYIANNAKIS, A\";i:6;s:12:\"TSAROUCHA, A\";i:7;s:12:\"ROMANIDIS, K\";i:8;s:12:\"KAKOLYRIS, S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:150:\"A dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with capecitabine (Xeloda) in patients with refractory solid tumors\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000090494\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:150:\"A dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with capecitabine (Xeloda) in patients with refractory solid tumors\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"69\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"463\";s:8:\"\u0000*\u0000epage\";s:3:\"469\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MALTEZOS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:14:\"AMARANTIDIS, K\";i:1;s:10:\"TRICHAS, M\";i:2;s:13:\"VASILIADIS, M\";i:3;s:14:\"TOROMANIDOU, M\";i:4;s:11:\"CHATZAKI, E\";i:5;s:16:\"KARAYIANNAKIS, A\";i:6;s:12:\"TSAROUCHA, A\";i:7;s:12:\"ROMANIDIS, K\";i:8;s:12:\"KAKOLYRIS, S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:150:\"A dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with capecitabine (Xeloda) in patients with refractory solid tumors\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000090494\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:150:\"A dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with capecitabine (Xeloda) in patients with refractory solid tumors\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"69\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"463\";s:8:\"\u0000*\u0000epage\";s:3:\"469\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MALTEZOS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:14:\"AMARANTIDIS, K\";i:1;s:10:\"TRICHAS, M\";i:2;s:13:\"VASILIADIS, M\";i:3;s:14:\"TOROMANIDOU, M\";i:4;s:11:\"CHATZAKI, E\";i:5;s:16:\"KARAYIANNAKIS, A\";i:6;s:12:\"TSAROUCHA, A\";i:7;s:12:\"ROMANIDIS, K\";i:8;s:12:\"KAKOLYRIS, S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:150:\"A dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with capecitabine (Xeloda) in patients with refractory solid tumors\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
